3T Pro commercial launch

Tristel PLC

27 July 2026

Tristel plc

("Tristel" or the "Company")

3T Pro commercial launch

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces the commercial launch of 3T Pro, a premium tier within its 3T digital compliance platform. This launch marks the first time the Company has introduced a paid model for 3T, representing a significant step in Tristel's strategy to develop recurring digital revenue streams alongside its core product portfolio.

Since its introduction, 3T has been offered as a free-to-use tool to work alongside Tristel disinfection products, supporting healthcare providers with staff training management and compliance tracking. 3T Pro is built and maintained by the Company's well established in-house software team, whose ownership of the platform allows priorities to be reshaped quickly in response to customer feedback and the growing compliance, audit and operational demands of healthcare providers. This has enabled the introduction of enhanced asset tracking and lifecycle management, sophisticated dashboards, structured audit reporting, and a scalable data architecture to support future integrations.

The launch formalises a three-tier product structure: a free entry-level tier covering core training and compliance functionality; a mid-tier combining training management with device traceability; and 3T Pro, a premium tier delivering advanced customisation, workflows, reporting and audit readiness capabilities. To protect its installed base, Tristel will offer transitional licensing arrangements to existing users of traceability features, while customers upgrading to 3T Pro will access the full suite of advanced capabilities under standard commercial terms. The entry-level tier remains free to support broad accessibility and adoption across the healthcare sector.

Matt Fulford, Group Digital Director Tristel plc, said: "The launch of 3T Pro is an important milestone for the business. 3T has established itself as a trusted compliance tool across our customer base, and we are now in a position to offer a premium tier that reflects the platform's maturity and the increasing demands placed on healthcare providers. This is a meaningful step in building a scalable digital offering that complements our infection prevention products."

For further information please contact:

Tristel plc			Via Walbrook PR
Anna Wasyl, Interim Chief Executive Officer			https://investors.tristel.com/
Walbrook PR Ltd	Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus / Lianne Applegarth / Anna Dunphy		Mob: 07980 541 893/ 07584 391 303/ 07876 741 001
Cavendish Capital Markets Ltd			Tel: 020 7220 0500
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation. 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.